Progress on Broadly Neutralizing Antibodies, Injectable PrEP, and Other New HIV Prevention Strategies Announced at HIV Research for Prevention Conference

26 January 2021 – Important advances in HIV prevention research were announced today at the 4th HIV Research for Prevention Conference (HIVR4P // Virtual), convened by IAS – the International AIDS Society. Highlights included findings from a pair of trials evaluating whether infusions with a broadly neutralizing antibody (bNAb) can prevent HIV acquisition and positive…

A Landmark trial in East and Southern Africa finds injectable PrEP safe and effective for cisgender women

Regulatory review and introduction plans must be accelerated New York City, November 9, 2020— AVAC enthusiastically welcomes the news that another trial of the long-acting, injectable antiretroviral cabotegravir (CAB-LA) for HIV prevention for HIV pre-exposure prophylaxis (PrEP) has demonstrated safety and efficacy, this time among cisgender women. Today’s announcement from ViiV, the US National Institute of Allergy and…